Nov 27, 2019: QIAGEN and DiaSorin received FDA approval for the LIAISON QuantiFERON-TB Plus Test (QFT-Plus), the fourth-generation modern gold standard for latent tuberculosis (TB) detection, on DiaSorin’s LIAISON platforms.

This test was developed by QIAGEN and DiaSorin in order to offer streamlined laboratory automation for latent TB screening, supporting the conversion from tuberculin skin tests to modern blood-based QuantiFERON technology.

QFT-Plus users are gaining admittance to the LIAISON’s powerful, highly elastic automation for all throughput segments, as well as to LIAISON’s broad list of more than 100 tests. This test was introduced in Europe in 2018 and is planned for China in 2020. https://corporate.qiagen.com/newsroom/press-releases/2019/20191127_diasorin_fda